Live Yum Brands Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow HAEMONETICS CORP

Get SEC filing alerts via email and in your feed for HAEMONETICS CORP

HAE

HAEMONETICS CORP

About HAEMONETICS CORP

Haemonetics is a global medical technology company providing blood and plasma collection, processing, and management solutions. Its core segments include Plasma, Blood Center, and Hospital, offering devices, software, and services to enhance blood and plasma collection, transfusion safety, and patient care. The company serves blood centers, plasma manufacturers, hospitals, and healthcare providers worldwide, focusing on innovation, quality, and regulatory compliance to improve healthcare outcomes.
This description was generated via AI from an annual report. Updated 10 months ago.

Latest SEC Filings from HAEMONETICS CORP

1
1
HAEMONETICS CORP Haemonetics Reports $1.334 Billion Revenue with 2% Decrease, Strategic Acquisitions and Stock Repurchase Announced

Via official filing (AI summary) | 2 months ago | 0 comments

2
1
HAEMONETICS CORP Haemonetics Reports 2.7% Revenue Decline in Q3 Fiscal 2026, Operating Income Increases 14.2%

Via official filing (AI summary) | 6 months ago | 0 comments

3
1
HAEMONETICS CORP Haemonetics Reports 5.3% Revenue Decline in Q2 Fiscal 2026, Operating Income Increases 13.1%

Via official filing (AI summary) | 9 months ago | 0 comments

4
1
HAEMONETICS CORP Haemonetics Reports 4.4% Revenue Decline in Q1 Fiscal 2026, Operating Income Rises 35.5%

Via official filing (AI summary) | 12 months ago | 0 comments

5
1
HAEMONETICS CORP Haemonetics Corporation Reports $1.36 Billion Revenue with 4% Growth for Fiscal Year Ending March 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
HAEMONETICS CORP Haemonetics Reports 3.7% Revenue Growth to $348.5 Million in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
HAEMONETICS CORP Haemonetics Reports Strong Financial Performance with 8.6% Revenue Growth and 35.8% Net Income Increase

Via official filing (AI summary) | over 1 year ago | 0 comments